drugset / Trial / NCT06038422
GTP Regimen in the Treatment of Refractory/Recurrent HLH
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to learn about efficacy and safety of GTP regimen in refractory/recurrent hemophagocytic lymphohistiocytosis. The main questions it aims to answer are: * Overall remission rate of GTP regimen in R/R HLH * Adverse effect of GTP regimen Participants will be treated with GTP regimen
Timeline
- Start
- 2023-09-15
- Primary completion
- 2024-09-15
- Completion
- 2025-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Emapalumab | Monoclonal antibody | — | — |
| Subject | Methylprednisolone | Other / unclassified | — | — |
| Subject | Teniposide | Small molecule | — | — |